---
title: "systemic_therapies-of-hepatocellular_carcinoma"
date: "2024-06-20"
tags:
  - building
---

> ðŸŒ± created from: [[hepatocellular carcinoma]]

# systemic_therapies-of-hepatocellular_carcinoma

# Summary of Clinical Trials for Liver Cancer Treatments

- **Atezolizumab/Bevacizumab vs. Sorafenib**

  - Atezolizumab/Bevacizumab (C-P Class A only) improves OS vs. sorafenib (median OS 19.2 vs. 13.4 mos)
    - Ref: IMbrave 150, NEJM 2020;382:1894; JCO 2021; 39(3_suppl):267
  - Evaluate & treat esophageal varices before initiating treatment
  - OS benefit seen in antidrug antibody (ADA) negative patients but not ADA positive patients
    - Ref: Cancer Research 2021;81(13_suppl):CT185

- **Sorafenib vs. Placebo**

  - Sorafenib (C-P Class A only) improves OS vs. placebo (median OS 10.7 vs. 7.9 mos)
    - Ref: SHAPR, NEJM 2008;359:378; Lancet Oncol 2009;10:25
  - May be considered for C-P class B7

- **Lenvatinib vs. Sorafenib**
  - Lenvatinib (C-P Class A only) is noninferior to sorafenib (median OS 13.6 vs. 12.3 mos)
    - Ref: REFLECT, Lancet 2018:391:1163

| Treatment                | Median OS (months) | Reference(s)                        |
| ------------------------ | ------------------ | ----------------------------------- |
| Atezolizumab/Bevacizumab | 19.2               | IMbrave 150, NEJM 2020; JCO 2021    |
| Sorafenib                | 13.4               | Cancer Research 2021                |
| Sorafenib (vs. Placebo)  | 10.7               | SHAPR, NEJM 2008; Lancet Oncol 2009 |
| Lenvatinib               | 12.3               | REFLECT, Lancet 2018                |
